GS-441524, a nucleoside analog, has garnered significant attention in the veterinary world for its potential in treating feline infectious peritonitis (FIP). As researchers and veterinarians delve deeper into its pharmacological properties, we uncover fascinating insights into how this compound interacts with feline physiology. In this comprehensive exploration, we'll examine the absorption, bioavailability, metabolism, and ability of GS 441524 powder to cross the blood-brain barrier, shedding light on its effectiveness as an FIP medication.
1.General Specification(in stock)
(1)Injection
20mg, 6ml; 30mg,8ml; 40mg,10ml
(2)Tablet
25/45/60/70mg
(3)API(Pure powder)
(4)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-1-049
GS-441524 CAS 1191237-69-0
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide GS 441524 powder, please refer to the following website for detailed specifications and product information.
Absorption and Bioavailability of GS-441524 Powder in Cats
Understanding the absorption and bioavailability of GS-441524 is crucial for determining its efficacy in treating FIP. These factors play a pivotal role in how the medication is distributed throughout a cat's body and ultimately reaches the target sites where the virus resides.
Gastrointestinal Absorption of GS-441524
When administered orally, GS-441524 undergoes absorption primarily in the small intestine. The compound's molecular structure allows it to pass through the intestinal epithelium relatively efficiently. However, the rate and extent of absorption can vary depending on several factors, including the cat's gastrointestinal pH, presence of food, and individual physiological differences.
Bioavailability Factors Influencing GS-441524 Effectiveness
The bioavailability of GS-441524 refers to the fraction of the administered dose that reaches systemic circulation unchanged. This parameter is crucial for determining the appropriate dosage and ensuring therapeutic efficacy. Studies have shown that the bioavailability of oral GS-441524 in cats is relatively high, typically ranging from 70-80%. This high bioavailability contributes to its effectiveness as an FIP medication, allowing a significant portion of the drug to reach its intended targets.
Impact of Formulation on Absorption
The formulation of GS 441524 powder can significantly impact its absorption profile. Liquid formulations tend to be absorbed more rapidly than solid forms, leading to quicker onset of action. Additionally, some compounded formulations may include excipients that enhance solubility and permeability, potentially improving overall bioavailability.
Half-Life and Metabolism: How Long Does GS-441524 Stay Active?
The duration of GS-441524's activity in the feline body is a critical factor in determining dosing regimens and assessing its long-term efficacy in managing FIP. Understanding the compound's half-life and metabolism provides valuable insights into its pharmacokinetic profile.
Plasma Half-Life of GS-441524
The plasma half-life of GS-441524 in cats has been reported to be approximately 3-4 hours. This relatively short half-life necessitates frequent dosing to maintain therapeutic levels in the body. However, it's important to note that the intracellular half-life of the active metabolite may be longer, contributing to sustained antiviral effects between doses.
Metabolic Pathways and Elimination
GS-441524, a widely used fip medication, undergoes metabolism primarily in the liver, where it is converted to its active form, GS-441524 triphosphate. This metabolite is responsible for the compound's antiviral activity. The primary route of elimination is through renal excretion, with a small portion eliminated via fecal excretion.
Factors Affecting Metabolism and Elimination
Several factors can influence the metabolism and elimination of GS-441524 in cats:
Hepatic function: Cats with impaired liver function may experience altered metabolism of the drug.
Renal function: Given the primary route of elimination is through the kidneys, renal impairment can affect drug clearance.
Age: Older cats may have reduced metabolic and eliminatory capacities, potentially leading to drug accumulation.
Concurrent medications: Some drugs may interact with GS-441524, affecting its metabolism or elimination.
Does GS-441524 Cross the Blood-Brain Barrier for Neurological FIP?
The ability of GS-441524 to cross the blood-brain barrier (BBB) is of particular interest, especially in cases of neurological FIP. This characteristic determines the compound's potential to treat FIP infections that have spread to the central nervous system.
Research has shown that GS-441524 does indeed cross the blood-brain barrier, albeit to a limited extent. This ability is crucial for treating neurological manifestations of FIP, which can be particularly challenging to manage. The compound's relatively small molecular size and lipophilic nature contribute to its capacity to penetrate the BBB.
Studies examining the concentrations of GS-441524 in cerebrospinal fluid (CSF) have found detectable levels following systemic administration. However, the CSF concentrations are typically lower than those observed in plasma, reflecting the selective permeability of the BBB. This underscores the importance of appropriate dosing strategies when targeting neurological FIP.
The ability of GS 441524 powder to cross the BBB has significant implications for treating neurological FIP:
Higher doses may be necessary to achieve therapeutic concentrations in the CNS.
Combination therapies or novel delivery methods may be explored to enhance CNS penetration.
Monitoring of neurological symptoms and CSF analysis may be crucial in assessing treatment efficacy.
Researchers are exploring various strategies to enhance the BBB penetration of GS-441524, including:
Nanoparticle formulations that can more readily cross the BBB
Prodrug approaches that leverage specific transporters at the BBB
Temporary disruption of the BBB to increase drug penetration
These approaches hold promise for improving the efficacy of GS-441524 in treating neurological FIP cases.
Conclusion
The pharmacological properties of GS-441524 reveal a compound with promising characteristics for treating FIP in cats. Its high bioavailability, coupled with its ability to cross the blood-brain barrier, makes it a valuable tool in the fight against this previously fatal disease. While its relatively short half-life necessitates frequent dosing, ongoing research into novel formulations and delivery methods may lead to improved pharmacokinetic profiles in the future.
As our understanding of GS-441524's pharmacology deepens, veterinarians and researchers can refine treatment protocols, optimize dosing regimens, and potentially expand its applications to other feline viral infections. The continued study of this remarkable compound holds great promise for advancing feline medicine and improving the lives of cats affected by FIP.
For pharmaceutical companies, research institutions, and veterinary clinics seeking high-quality GS 441524 powder for clinical studies or compounding purposes, Shaanxi BLOOM TECH Co., Ltd. offers premium-grade products manufactured in our GMP-certified facilities. With our expertise in chemical synthesis and purification techniques, we ensure the highest standards of quality and purity. To learn more about our GS-441524 powder and other specialty chemicals, please contact our sales team at Sales@bloomtechz.com. Our dedicated experts are ready to assist you with your specific requirements and provide tailored solutions for your research or clinical needs.
References
1. Pedersen, N. C., et al. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery, 21(4), 271-281.
2. Murphy, B. G., et al. (2018). The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Veterinary Microbiology, 219, 226-233.
3. Kim, Y., et al. (2020). Pharmacokinetics and Tissue Distribution of Remdesivir and Its Metabolites in Mice. Antimicrobial Agents and Chemotherapy, 64(11), e01049-20.
4. Dickinson, P. J., et al. (2020). Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. Journal of Veterinary Internal Medicine, 34(4), 1587-1593.